|
|
原发CD5阳性弥漫大B细胞淋巴瘤一例并文献复习
|
Abstract:
目的：探讨CD5阳性弥漫大B细胞淋巴瘤(DLBCL)的临床特点及治疗方案，提高对该病的认识。方法：回顾性分析临沂市中心医院2020年5月收治的1例CD5 (+) DLBCL患者资料，并结合相关文献进行讨论。结果：该患者相较于CD5 (？) DLBCL恶性程度更高，在接受R-CHOP方案、R-GDP方案以及泽布替尼 + BR方案治疗后，仍预后不良。结论：CD5 (+) DLBCL较少见，具有独特的临床特点，治疗反应差，在临床中我们应重视CD5在DLBCL中的表达。
Objective: To explore the clinical characteristics and treatment options of CD5-positive diffuse large B-cell lymphoma (DLBCL) and to raise awareness of the disease. Methods: Retrospective analysis of the data of 1 CD5 (+) DLBCL patient admitted to Linyi Center Hospital in May 2020, and discussion in conjunction with relevant literature. Results: The patient had a higher malignancy degree than CD5 (？) DLBCL and still had poor prognosis after receiving treatment from R-CHOP, R-GDP, and Zanubrutinib + BR. Conclusion: CD5 (+) DLBCL is rare and has unique clinical characteristics, poor treatment response, in clinic, we should pay attention to CD5 expression in DLBCL.
| [1] | Susanibar-Adaniya, S. and Barta, S.K. (2021) Update on Diffuse Large B Cell Lymphoma: A Review of Current Data and Potential Applications on Risk Stratification And Management. American Journal of Hematology, 96, 617-629.
https://doi.org/10.1002/ajh.26151 |
| [2] | Xu-Monette, Z.Y., Tu, M., Jabbar, K.J., Cao, X., Tzankov, A., Visco, C., Nagarajan, L., Cai, Q., Montes-Moreno, S., An, Y., Dybkaer, K., Chiu, A., Orazi, A., Zu, Y., Bhagat, G., Richards, K.L., Hsi, E.D., Choi, W.W., van Krieken, J.H., Huh, J., Young, K.H., et al. (2015) Clinical and Biological Significance of de Novo CD5+ Diffuse Large B-Cell Lymphoma in Western Countries. Oncotarget, 6, 5615-5633. https://doi.org/10.18632/oncotarget.3479 |
| [3] | Lydyard, P.M., Jewell, A.P., Jamin, C. and Youinou, P.Y. (1999) CD5 B Cells and B-Cell Malignancies. Current Opinion in Hematology, 6, 30-36. https://doi.org/10.1097/00062752-199901000-00006 |
| [4] | Na, H.Y., Choe, J.Y., Shin, S.A., Kim, H.J., Han, J.H., Kim, H.K., Oh, S.H. and Kim, J.E. (2019) Characteristics of CD5-Positive Diffuse Large B-Cell Lymphoma among Koreans: High Incidence of BCL2 and MYC Double-Expressors. PLoS ONE, 14, e0224247. https://doi.org/10.1371/journal.pone.0224247 |
| [5] | Yamaguchi, M., Nakamura, N., Suzuki, R., Kagami, Y., Okamoto, M., Ichinohasama, R., Yoshino, T., Suzumiya, J., Murase, T., Miura, I., Ohshima, K., Nishikori, M., Tamaru, J., Taniwaki, M., Hirano, M., Morishima, Y., Ueda, R., Shiku, H. and Nakamura, S. (2008) De Novo CD5+ Diffuse Large B-Cell Lymphoma: Results of a Detailed Clinicopathological Review in 120 Patients. Haematologica, 93, 1195-1202. https://doi.org/10.3324/haematol.12810 |
| [6] | Montalbán, C., Díaz-López, A., Martín, A., Baile, M., Sanchez, J.M., Sancho, J.M., García, O., Novelli, S., Monter-Rovira, A., Salar, A., Bastos, M., Gutiérrez, A., Bento, L., Córdoba, R., Arquero, T., González de Villambrosia, S., Barranco, G., De O？a, R., López Guillermo, A., Rodriguez Salazar, M.J., et al. (2018) Differential Prognostic Impact of GELTAMO-IPI in Cell of Origin Subtypes of Diffuse Large B Cell Lymphoma as Defined by the Hans Algorithm. British Journal of Haematology, 182, 534-541. https://doi.org/10.1111/bjh.15446 |
| [7] | Xu, Y., Sun, W. and Li, F. (2020) De Novo CD5+ Diffuse Large B-Cell Lymphoma: Biology, Mechanism, and Treatment Advances. Clinical Lymphoma, Myeloma & Leukemia, 20, e782-e790. https://doi.org/10.1016/j.clml.2020.05.003 |
| [8] | Durani, U. and Ansell, S.M. (2021) CD5+ Diffuse Large B-Cell Lymphoma: A Narrative Review. Leukemia & Lymphoma, 1-9. https://doi.org/10.1080/10428194.2021.1953010 |
| [9] | Qu, Q., Li, Y., Fang, X., Zhang, L., Xue, C., Ge, X., Wang, X. and Jiang, Y. (2019) Differentially Expressed tRFs in CD5 Positive Relapsed & Refractory Diffuse Large B Cell Lymphoma and the Bioinformatic Analysis for Their Potential Clinical Use. Biology Direct, 14, 23. https://doi.org/10.1186/s13062-019-0255-8 |
| [10] | Ennishi, D., Takeuchi, K., Yokoyama, M., Asai, H., Mishima, Y., Terui, Y., Takahashi, S., Komatsu, H., Ikeda, K., Yamaguchi, M., Suzuki, R., Tanimoto, M. and Hatake, K. (2008) CD5 Expression Is Potentially Predictive of Poor Outcome among Biomarkers in Patients with Diffuse Large B-Cell Lymphoma Receiving Rituximab plus CHOP Therapy. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 19, 1921-1926.
https://doi.org/10.1093/annonc/mdn392 |
| [11] | Hayashi, K., Nagasaki, E., Kan, S., Ito, M., Kamata, Y., Homma, S. and Aiba, K. (2016) Gemcitabine Enhances Rituximab-Mediated Complement-Dependent Cytotoxicity to B Cell Lymphoma by CD20 Upregulation. Cancer Science, 107, 682-689. https://doi.org/10.1111/cas.12918 |
| [12] | Aribi, M., Mesli, N., Remla, N., Sari, B.E., Taleb, A., Touhami, H., Bekadja, M.A., Zouaoui-Benhadji, Z., Bouzid, K. and Meguenni, K. (2010) Gemcitabine and Treatment of Diffuse Large B-Cell Lymphoma in Relapsed or Refractory Elderly Patients: A Prospective Randomized Trial in Algeria. Journal of Cancer Research and Therapeutics, 6, 41-46.
https://doi.org/10.4103/0973-1482.63572 |
| [13] | Lucas, F. and Woyach, J.A. (2019) Inhibiting Bruton’s Tyrosine Kinase in CLL and Other B-Cell Malignancies. Targeted oncology, 14, 125-138. https://doi.org/10.1007/s11523-019-00635-7 |
| [14] | Cai, J., Tian, X., Ma, S., Zhong, L., Li, W., Wang, L., Guo, L., Li, Z., Wu, Y., Zhong, G., Huang, H., Xia, Z., Xia, Y., Liu, P., Su, N., Fang, Y., Zhang, Y. and Cai, Q. (2021) A Nomogram Prognostic Index for Risk-Stratification in Diffuse Large B-Cell Lymphoma in the Rituximab Era: A Multi-Institutional Cohort Study. British Journal of Cancer, 125, 402-412. https://doi.org/10.1038/s41416-021-01434-6 |
| [15] | Miyazaki, K., Asano, N., Yamada, T., Miyawaki, K., Sakai, R., Igarashi, T., Nishikori, M., Ohata, K., Sunami, K., Yoshida, I., Yamamoto, G., Takahashi, N., Okamoto, M., Yano, H., Nishimura, Y., Tamaru, S., Nishikawa, M., Izutsu, K., Kinoshita, T., Suzumiya, J., et al. (2020) DA-EPOCH-R Combined with High-Dose Methotrexate in Patients with Newly Diagnosed Stage II-IV CD5-Positive Diffuse Large B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Study. Haematologica, 105, 2308-2315. https://doi.org/10.3324/haematol.2019.231076 |
